Increased use of immunoglobulin preparations and its factors in Japan

DOI Web Site 1 Citations 1 References Open Access
  • Sugawa Makiko
    Department of Health Care Management and Planning, Tokyo Medical and Dental University Graduate School of Medical and Dental Science
  • Sagawa Kimitaka
    Japanese Red Cross Fukuoka Blood Center
  • Ohyama Katsunori
    Department of Health Care Management and Planning, Tokyo Medical and Dental University Graduate School of Medical and Dental Science The sales department, GlaxoSmithKline Co., Ltd
  • Henzan Tomoko
    Center for Cellular and Molecular Medicine, Kyushu University Hospital
  • Nagai Kazuhiro
    Transfusion and Cell Therapy Unit, Nagasaki University Hospital
  • Nakajima Kazunori
    Japanese Red Cross Blood Service Headquarters
  • Kawahara Kazuo
    Department of Health Care Management and Planning, Tokyo Medical and Dental University Graduate School of Medical and Dental Science

Bibliographic Information

Other Title
  • 我が国における免疫グロブリン製剤の使用量増加とその要因

Search this article

Description

<p>In recent years, the shortage of immunoglobulin has become a serious issue worldwide. Japan is facing a similar situation, especially since 2019, due to the rapid increase in immunoglobulin usage, and the need for urgent imports is unavoidable. We analyzed two factors that immediately preceded the surge in immunoglobulin consumption: approved indications for the prevention of chronic inflammatory demyelinating polyneuropathy (CIDP) progression and launches of concentrated preparations. Although the use of the immunoglobulin for CIDP demonstrated a continuing upward trend, there was no significant increase before or after approval. However, the launch of a concentrated preparation, 10% Venoglobulin® (Japan Blood Products Organization (JB) ), has led to shorter treatment times and changes in the form of treatment from inpatient to outpatient or home-based care, especially in patients with hypogammaglobulinemia and agammaglobulinemia (PID/SID) requiring continuous administration, which has resulted in a sharp increase in the use of the immunoglobulin. This may be because treatment needs hidden by hospitalization were unearthed with the increased availability of outpatient treatment. In the future, as companies strive to shorten treatment time, additional needs will be created for diseases that require continuous medication.</p><p>In the midst of the heated international plasma products market, careful debate is needed on how far to promote the appropriate use of immunoglobulin, how to extend approved indications, and how to adjust the quantity of demand.</p>

Journal

Citations (1)*help

See more

References(1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top